By Monica E. Oss, Chief Executive Officer What a difference a couple years can make. I was reviewing my 2020 presentation to the members of MHCA (formerly the Mental Health Corporations of America) at their 35th anniversary gathering, and I was struck by what was missing from my timeline of the science of mental health treatment—the many new advances in digital treatment interventions (see The Future Has Already Happened). Just this September, the U.S. Food and Drug Administration (FDA) approved the first-ever twice-yearly injectable antipsychotic (see Janssen Announces U.S. FDA Approval of Invega Hafyera). And we recently saw the approval of a somewhat controversial new pharmaceutical agent…